J&J Unit's $65M Settlement in Drug-Blocking Antitrust Case

BALTIMORE, MD – March 13, 2026 – A Johnson & Johnson subsidiary, Actelion Pharmaceuticals, has agreed to a $65 million settlement to resolve a long-running antitrust class action lawsuit, bringing a dramatic end to a case that was less than two weeks away from a jury trial. The settlement, which received preliminary court approval today, addresses allegations that Actelion illegally suppressed competition for its life-saving pulmonary hypertension drug, Tracleer, costing health plans and other payers over $100 million.

The lawsuit, spearheaded by the Government Employees Health Association (GEHA), accused Actelion of orchestrating a multi-pronged scheme to prevent generic drug makers from obtaining samples of Tracleer. These samples are a critical and legally required component for developing a lower-cost generic equivalent, as they are used to conduct bioequivalence tests mandated by the Food and Drug Administration (FDA).

The High Price of Delay

At the heart of the case was the claim that Actelion deliberately created an impenetrable fortress around its blockbuster drug. According to the plaintiffs, the company not only refused to sell Tracleer samples directly to generic competitors but also embedded restrictive clauses in its contracts with specialty pharmacies, contractually forbidding them from providing samples to any potential rivals. This effectively sealed off every possible avenue for generic development.

The alleged scheme proved devastatingly effective. Despite the primary patent for Tracleer expiring in November 2015, no generic version reached the market for nearly four years. During this extended monopoly, Actelion continued to charge premium prices for the drug, which treats pulmonary arterial hypertension (PAH), a rare and potentially fatal condition. With an annual cost soaring to approximately $75,000 per patient, the delay translated into massive overpayments by third-party payers like GEHA, which provides health benefits to federal employees.

“On behalf of our client and the certified Class of unions, employers and other entities that pay for prescription benefits on behalf of millions of patients, we are very pleased with this settlement, which represents a substantial recovery — nearly fifty percent of our conservative single damages estimate,” said Sharon Robertson, a partner at Cohen Milstein and Co-Lead Counsel for the Class. “If the settlement receives final approval, it will deliver meaningful relief to the Class who purchased Tracleer and generic Tracleer, bringing well-deserved resolution after more than seven years of hard-fought litigation.”

A Tortuous Legal Path to Accountability

The road to the $65 million settlement was a legal marathon, marked by significant setbacks and a crucial appellate victory. Originally filed in 2018, the case was dismissed a year later by a Maryland district court, which found the claims were filed too late under the four-year statute of limitations and that the plaintiff lacked standing in certain states.

However, the plaintiffs' legal team persevered, appealing the decision to the U.S. Court of Appeals for the Fourth Circuit. In a pivotal 2021 ruling, the appellate court revived the case, finding that the clock on the statute of limitations began not when Actelion committed the anticompetitive acts, but when the plaintiffs actually suffered the financial injury by paying inflated prices after the patent had expired. This decision provided a critical opening for this and similar antitrust cases.

Following the remand, the case gained momentum. In September 2024, the district court certified the class of third-party payers and simultaneously denied Actelion's motion for summary judgment, setting the stage for a 25-day jury trial that was scheduled to begin on March 2, 2026. The eve-of-trial settlement avoids the risks and expenses of a protracted courtroom battle for both sides.

Throughout the litigation, Actelion reportedly defended its actions by citing its duty to manage the drug's safety risks under a federally mandated Risk Evaluation and Mitigation Strategy (REMS) program. Plaintiffs argued this safety protocol was used as a pretext to execute an anticompetitive monopoly-extending scheme.

Patients and Precedent in the Crosshairs

While the lawsuit centered on financial damages to payers, the human cost of delayed generic competition casts a long shadow. Pulmonary arterial hypertension is a chronic, progressive disease that causes dangerously high blood pressure in the arteries of the lungs, forcing the heart to work harder to pump blood. It affects a relatively small population of 10,000 to 20,000 people in the U.S., most of them women, making them a vulnerable group reliant on a limited number of effective treatments.

The tactics alleged in the Tracleer case are part of a broader, well-documented industry playbook of “evergreening” or “product hopping.” These strategies are designed to extend a drug’s profitability long after its core patent protection ends. This can involve making minor changes to a drug's formulation to secure new patents, as seen in cases involving the cholesterol drug TriCor, or aggressively switching patients to a new, patent-protected version, as was challenged in the landmark case involving the Alzheimer's drug Namenda.

The Actelion case highlights a different but equally potent tactic: weaponizing drug distribution and safety programs to starve potential competitors of the materials they need to enter the market. Such strategies are seen by critics as a way to game the system established by the Hatch-Waxman Act, which was designed to balance patent protection with the promotion of affordable generic alternatives.

This settlement serves as a potent warning shot to the pharmaceutical industry. By securing a significant financial recovery and forcing the issue just before a public trial, the plaintiffs have highlighted the legal risks of engaging in conduct that thwarts generic competition. The outcome strengthens the precedent that a company's refusal to deal with competitors can be subject to antitrust scrutiny, especially when it serves to unlawfully maintain a monopoly and inflate healthcare costs for everyone.